Boehringer Ingelheim and 3T Biosciences form $268m partnership to develop next-generation cancer immunotherapies
pharmafile | January 16, 2023 | News story | Medical Communications |
Germany-based Boehringer Ingelheim and US company 3T Biosciences have entered into a strategic collaboration and licensing agreement to research and develop new cancer therapies to address high unmet patient need.
3T Biosciences will bring their best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform to the table, with Boehringer Ingelheim providing a two-pronged research strategy looking at cancer cell-directed and immune cell-targeting compounds. Boehringer Ingelheim will also provide patient-derived TCR data to help 3T Biosciences identify antigens using its 3T-TRACE discovery platform.
3T Biosciences will receive an upfront payment as well as research and development support, and is eligible for $268m in discovery, preclinical, clinical, regulatory and commercial milestones. Both will receive royalties on any future Boehringer Ingelheim, or 3T Biosciences, products to come from the partnership.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, PhD, Global Head of Cancer Immunology and Immune Modulation at Boehringer Ingelheim.
Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences stated: “On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments. 3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumour indications and across patient populations.”
James Spargo
